CVRx (NASDAQ:CVRX) Releases Quarterly Earnings Results, Misses Expectations By $0.01 EPS

CVRx (NASDAQ:CVRX) released its earnings results on Thursday. The company reported ($0.53) earnings per share for the quarter, missing the consensus estimate of ($0.52) by ($0.01), FiscalAI reports. CVRx had a negative return on equity of 133.84% and a negative net margin of 84.93%.The company had revenue of $15.71 million during the quarter, compared to the consensus estimate of $15.55 million.

Here are the key takeaways from CVRx’s conference call:

• 2026 revenue guidance was lowered to $58 million–$60 million, with third-quarter revenue expected at $13.5 million–$14.5 million, reflecting weaker anticipated second-half performance.
• Sales execution has been hampered by high turnover and slower-than-expected ramping of new territory managers, particularly in several regions with less-tenured leadership; CVRx does not expect to add sales territories for the rest of 2026.
• A major Medicare Advantage payer’s use of new prior-authorization tactics has pushed its 30-day approval rate below 30%, making physicians more hesitant to recommend Barostim for patients covered by that plan.
• Reimbursement trends outside that payer are improving, including a 60% overall Medicare Advantage 30-day approval rate, approval rates above 90% with Humana, approximately 96% payment across traditional Medicare contractors, and higher inpatient payment rates.
• CVRx reported second-quarter revenue of $15.7 million, up 16% year over year, and said the BENEFIT-HF trial is ahead of expectations for site activation and enrollment; however, the company also disclosed a Department of Justice civil investigative demand related to certain sales and marketing practices.

CVRx Stock Performance

Shares of CVRX stock opened at $2.39 on Friday. The company has a quick ratio of 8.89, a current ratio of 10.20 and a debt-to-equity ratio of 2.01. The business has a 50 day moving average of $5.19 and a two-hundred day moving average of $6.49. CVRx has a 52 week low of $2.30 and a 52 week high of $11.30. The company has a market cap of $63.43 million, a P/E ratio of -1.21 and a beta of 0.81.

Analyst Ratings Changes

CVRX has been the subject of several research analyst reports. Lake Street Capital lowered CVRx from a “buy” rating to a “hold” rating and set a $3.50 price objective for the company. in a report on Friday. Craig Hallum downgraded CVRx from a “buy” rating to a “hold” rating and set a $4.00 target price on the stock. in a report on Friday. Canaccord Genuity Group reiterated a “buy” rating and issued a $10.00 target price on shares of CVRx in a research report on Tuesday, April 14th. Weiss Ratings reiterated a “sell (e+)” rating on shares of CVRx in a report on Monday. Finally, Piper Sandler lowered CVRx from an “overweight” rating to a “neutral” rating and set a $4.00 price target on the stock. in a research report on Friday. One research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, CVRx presently has an average rating of “Hold” and an average target price of $6.90.

Institutional Trading of CVRx

Institutional investors and hedge funds have recently made changes to their positions in the stock. Virtu Financial LLC bought a new position in CVRx during the 4th quarter worth $79,000. Corient Private Wealth LLC bought a new stake in shares of CVRx during the fourth quarter valued at approximately $81,000. XTX Topco Ltd bought a new stake in shares of CVRx during the fourth quarter valued at approximately $90,000. Alliancebernstein L.P. boosted its position in shares of CVRx by 10.7% during the third quarter. Alliancebernstein L.P. now owns 17,560 shares of the company’s stock worth $142,000 after buying an additional 1,700 shares during the period. Finally, Wells Fargo & Company MN grew its holdings in CVRx by 61.3% in the 4th quarter. Wells Fargo & Company MN now owns 20,266 shares of the company’s stock worth $144,000 after buying an additional 7,705 shares in the last quarter. 75.27% of the stock is currently owned by institutional investors and hedge funds.

Key CVRx News

Here are the key news stories impacting CVRx this week:

• Positive Sentiment: CVRx reported second-quarter revenue of $15.71 million, slightly above the $15.55 million analyst consensus. Its per-share loss of $0.53 was also an improvement from a $0.57 loss a year earlier, although it narrowly missed the $0.52 consensus loss. CVRx Reports Second Quarter 2026 Financial and Operating Results
• Positive Sentiment: Despite downgrading the shares to “hold,” Lake Street Capital and Craig Hallum set price targets of $3.50 and $4.00, respectively—above the current trading level—suggesting potential recovery if execution improves. The Fly analyst ratings
• Neutral Sentiment: Johnson Fistel said it is investigating whether CVRx or certain executives violated securities laws in connection with the guidance reduction and sales-execution disclosures. The announcement is an investigation notice, not a finding of wrongdoing, but it adds headline and legal risk. Johnson Fistel investigation notice
• Negative Sentiment: CVRx cut third-quarter revenue guidance to $13.5 million-$14.5 million, well below the $16.9 million consensus, and reduced full-year 2026 revenue guidance to $58 million-$60 million from an implied level near the $65.4 million consensus. Management cited slower sales productivity and Medicare Advantage-related headwinds. CVRx forecasts 2026 revenue
• Negative Sentiment: The quarterly loss slightly exceeded expectations, while CVRx continues to report deeply negative profitability, including a negative net margin and negative return on equity. Analysts responded by downgrading the stock from “buy” to “hold,” reinforcing concerns about near-term growth and execution. CVRx Q2 2026 earnings call transcript

About CVRx

CVRx, Inc is a clinical-stage medical device company focused on developing a neuromodulation platform therapy for patients with cardiovascular disease. The company’s flagship product, the Barostim™ system, delivers targeted electrical stimulation to the carotid baroreceptors with the goal of modulating the body’s natural blood pressure control mechanisms. This minimally invasive, implantable therapy is designed to address unmet needs in individuals suffering from hypertension and heart failure.

The Barostim system is currently being evaluated in multiple clinical trials, including studies in resistant hypertension and advanced heart failure.